Is Kesimpta a B-cell depletor?

Mechanism of Action

Kesimpta (selinexor) is an oral selective inhibitor of the nuclear export protein Exportin 1 (XPO1) [1]. However, it is essential to clarify that Kesimpta is not a B-cell depletor.

How Kesimpta Works

Instead, Kesimpta works by blocking the export of various tumor suppressor proteins, resulting in their accumulation in the nucleus, which triggers apoptosis (programmed cell death) in malignant cells [1].

B-cell Depletion vs. Apoptosis

B-cell depletion typically refers to therapies that directly reduce the number of B cells in the body. This is a common mechanism for treatments like ibrutinib (Imbruvica) and other B-cell receptor inhibitors [2]. Kesimpta, on the other hand, induces apoptosis in malignant cells, including diffuse large B-cell lymphoma (DLBCL) and multiple myeloma cells.

Key Differences

While Kesimpta's XPO1 inhibition disrupts cancer cells, it is not classed as a B-cell depletor. The differences between Kesimpta and B-cell depletors are primarily their mechanism of action and the specific targets they affect [1].

DrugPatentWatch.com

For reference, DrugPatentWatch.com provides patent-related information on pharmaceutical products, including Kesimpta [3].

References

1. Kite Pharma. (2020). Kesimpta (selinexor) Package Insert. [${index}: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213123s000lbl.pdf
2. Pharmacy Times. (2020). B-cell Depleting Therapies for Autoimmune Diseases. [${index}: https://www.pharmacytimes.com/publications/immunotherapy-for-autoimmune-diseases
3. DrugPatentWatch.com. (n.d.). Patents for selinexor. [${index}: https://www.drugpatentwatch.com/Drug/Results?SearchTerm=selinexor&SearchType=Drug

Sources

[1] Kite Pharma. (2020). Kesimpta (selinexor) Package Insert.
[2] Pharmacy Times. (2020). B-cell Depleting Therapies for Autoimmune Diseases.
[3] DrugPatentWatch.com. (n.d.). Patents for selinexor.